Breaking News

FDA Committee Supports Maternal Immunization with RSV Vaccine Candidate to Help Protect Infants

May 19, 2023 • 7:45 am CDT
from Pixabay
(Precision Vaccinations)

Pfizer Inc. today announced that the U.S. Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted that the available data support the efficacy and safety of its unadjuvanted bivalent respiratory syncytial virus (RSV) prefusion F vaccine candidate RSVpreF or PF-06928316 (ABRYSVO™).

The vaccine candidate is under FDA review for preventing medically attended lower respiratory tract disease (MA-LRTD) and severe MA-LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant women.

The VRBPAC voted 14 to 0 on effectiveness and 10 to 4 on safety.

“We are encouraged by the outcome of today’s VRBPAC meeting as it is a critical step forward in the scientific community’s long-sought-after goal to help prevent RSV disease in infants during their most vulnerable first six months of life,” said Annaliesa Anderson, Ph.D., Senior Vice President and Chief Scientific Officer, Vaccine Research and Development, Pfizer, in a related press release.

Additional RSV vaccine and monoclonal antibody news are posted by Precision Vaccinations.